_id
6915e705bc934aba376b1ac8
Ticker
PRLD
Name
Prelude Therapeutics Inc
Exchange
NASDAQ
Address
175 Innovation Boulevard, Wilmington, DE, United States, 19805
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://preludetx.com
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Last Close
1.63
Volume
474326
Current Price
1.71
Change
4.907975460122705
Last Updated
2025-12-03T12:21:33.383Z
Image
data:image/webp;base64,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
Ipo Date
2020-09-25T00:00:00.000Z
Market Cap
84553792
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.38799999999999996
Sentiment Sources
9
Rating
3.75
Target Price
4
Strong Buy
1
Buy
2
Hold
0
Sell
1
Strong Sell
0
Current Quarter
2025-09-30
Revenue
6500000
Cost Of Revenue
425000
Gross Profit
6075000
Operating Expenses
26493000
Operating Income
-20418000
Interest Expense
-
Pretax Income
-19725000
Net Income
-19725000
Eps
-0.2590883293126809
Dividends Per Share
-
Shares Outstanding
50015011
Income Tax Expense
-
EBITDA
-19300000
Operating Margin
-314.1230769230769
Total Other Income Expense Net
693000
Cash
47532000
Short Term Investments
7425000
Receivables
-
Inventories
-
Total Current Assets
58330000
Property Plant Equipment
33080000
Total Assets
94755000
Payables
2533000
Short Term Debt
2727000
Long Term Debt
-
Total Liabilities
36221000
Equity
58534000
Depreciation
425000
Change In Working Capital
-2572000
Cash From Operations
-19115000
Capital Expenditures
0
Cash From Investing
40091000
Cash From Financing
-5000
Net Change In Cash
21780000
PE
-
PB
2.224114126319746
ROE
-33.69836334438104
ROA
-20.816843438340985
FCF
-19115000
Fcf Percent
-2.940769230769231
Piotroski FScore
1
Health Score
31
Deep Value Investing Score
4
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
1.5
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
3.5
Quality Investing Score
2
Value Investing Score
4
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
6500000
Quarters > 0 > income Statement > cost Of Revenue
425000
Quarters > 0 > income Statement > gross Profit
6075000
Quarters > 0 > income Statement > operating Expenses
26493000
Quarters > 0 > income Statement > operating Income
-20418000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-19725000
Quarters > 0 > income Statement > net Income
-19725000
Quarters > 0 > income Statement > eps
-0.2590883293126809
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
76132337
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-19300000
Quarters > 0 > income Statement > operating Margin
-314.1230769230769
Quarters > 0 > income Statement > total Other Income Expense Net
693000
Quarters > 0 > balance Sheet > cash
47532000
Quarters > 0 > balance Sheet > short Term Investments
7425000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
58330000
Quarters > 0 > balance Sheet > property Plant Equipment
33080000
Quarters > 0 > balance Sheet > total Assets
94755000
Quarters > 0 > balance Sheet > payables
2533000
Quarters > 0 > balance Sheet > short Term Debt
2727000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
36221000
Quarters > 0 > balance Sheet > equity
58534000
Quarters > 0 > cash Flow > net Income
-19725000
Quarters > 0 > cash Flow > depreciation
425000
Quarters > 0 > cash Flow > change In Working Capital
-2572000
Quarters > 0 > cash Flow > cash From Operations
-19115000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
40091000
Quarters > 0 > cash Flow > cash From Financing
-5000
Quarters > 0 > cash Flow > net Change In Cash
21780000
Quarters > 0 > ratios > PE
-0.2590883293126809
Quarters > 0 > ratios > PB
2.224114126319746
Quarters > 0 > ratios > ROE
-33.69836334438104
Quarters > 0 > ratios > ROA
-20.816843438340985
Quarters > 0 > ratios > FCF
-19115000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-2.940769230769231
Quarters > 0 > health Score
31
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
433000
Quarters > 1 > income Statement > gross Profit
-433000
Quarters > 1 > income Statement > operating Expenses
32194000
Quarters > 1 > income Statement > operating Income
-32194000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-31231000
Quarters > 1 > income Statement > net Income
-31231000
Quarters > 1 > income Statement > eps
-0.41096697432759804
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
75993941
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-31761000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
963000
Quarters > 1 > balance Sheet > cash
25752000
Quarters > 1 > balance Sheet > short Term Investments
47464000
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
76876000
Quarters > 1 > balance Sheet > property Plant Equipment
33888000
Quarters > 1 > balance Sheet > total Assets
114918000
Quarters > 1 > balance Sheet > payables
4962000
Quarters > 1 > balance Sheet > short Term Debt
2711000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
39080000
Quarters > 1 > balance Sheet > equity
75838000
Quarters > 1 > cash Flow > net Income
-31231000
Quarters > 1 > cash Flow > depreciation
433000
Quarters > 1 > cash Flow > change In Working Capital
739000
Quarters > 1 > cash Flow > cash From Operations
-26075000
Quarters > 1 > cash Flow > capital Expenditures
20000
Quarters > 1 > cash Flow > cash From Investing
11521000
Quarters > 1 > cash Flow > cash From Financing
37000
Quarters > 1 > cash Flow > net Change In Cash
-14517000
Quarters > 1 > ratios > PE
-0.41096697432759804
Quarters > 1 > ratios > PB
1.713516167488594
Quarters > 1 > ratios > ROE
-41.181202035918666
Quarters > 1 > ratios > ROA
-27.17676952261613
Quarters > 1 > ratios > FCF
-26095000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
39
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
435000
Quarters > 2 > income Statement > gross Profit
-435000
Quarters > 2 > income Statement > operating Expenses
34606000
Quarters > 2 > income Statement > operating Income
-34606000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-32085000
Quarters > 2 > income Statement > net Income
-32085000
Quarters > 2 > income Statement > eps
-0.42224727382038874
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
75986281
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-34171000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
2521000
Quarters > 2 > balance Sheet > cash
40269000
Quarters > 2 > balance Sheet > short Term Investments
58805000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
102403000
Quarters > 2 > balance Sheet > property Plant Equipment
34703000
Quarters > 2 > balance Sheet > total Assets
141260000
Quarters > 2 > balance Sheet > payables
5831000
Quarters > 2 > balance Sheet > short Term Debt
2653000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
38082000
Quarters > 2 > balance Sheet > equity
103178000
Quarters > 2 > cash Flow > net Income
-32085000
Quarters > 2 > cash Flow > depreciation
435000
Quarters > 2 > cash Flow > change In Working Capital
-6876000
Quarters > 2 > cash Flow > cash From Operations
-34231000
Quarters > 2 > cash Flow > capital Expenditures
47000
Quarters > 2 > cash Flow > cash From Investing
62186000
Quarters > 2 > cash Flow > cash From Financing
-160000
Quarters > 2 > cash Flow > net Change In Cash
27795000
Quarters > 2 > ratios > PE
-0.42224727382038874
Quarters > 2 > ratios > PB
1.2593434696349997
Quarters > 2 > ratios > ROE
-31.096745430227372
Quarters > 2 > ratios > ROA
-22.713436216905
Quarters > 2 > ratios > FCF
-34278000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
42
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
4000000
Quarters > 3 > income Statement > cost Of Revenue
489000
Quarters > 3 > income Statement > gross Profit
4000000
Quarters > 3 > income Statement > operating Expenses
37831000
Quarters > 3 > income Statement > operating Income
-33831000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-28731000
Quarters > 3 > income Statement > net Income
-28731000
Quarters > 3 > income Statement > eps
-0.3785571954781685
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
75896061
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-33342000
Quarters > 3 > income Statement > operating Margin
-845.7750000000001
Quarters > 3 > income Statement > total Other Income Expense Net
5100000
Quarters > 3 > balance Sheet > cash
12474000
Quarters > 3 > balance Sheet > short Term Investments
121140000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
135895000
Quarters > 3 > balance Sheet > property Plant Equipment
35466000
Quarters > 3 > balance Sheet > total Assets
175515000
Quarters > 3 > balance Sheet > payables
7732000
Quarters > 3 > balance Sheet > short Term Debt
2700000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
44056000
Quarters > 3 > balance Sheet > equity
131459000
Quarters > 3 > cash Flow > net Income
-28731000
Quarters > 3 > cash Flow > depreciation
489000
Quarters > 3 > cash Flow > change In Working Capital
4287000
Quarters > 3 > cash Flow > cash From Operations
-20744000
Quarters > 3 > cash Flow > capital Expenditures
53000
Quarters > 3 > cash Flow > cash From Investing
22118000
Quarters > 3 > cash Flow > cash From Financing
-34000
Quarters > 3 > cash Flow > net Change In Cash
1340000
Quarters > 3 > ratios > PE
-0.3785571954781685
Quarters > 3 > ratios > PB
0.987245181463422
Quarters > 3 > ratios > ROE
-21.85548345872097
Quarters > 3 > ratios > ROA
-16.36954106486625
Quarters > 3 > ratios > FCF
-20797000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-5.19925
Quarters > 3 > health Score
34
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
7000000
Annuals > 0 > income Statement > cost Of Revenue
1772000
Annuals > 0 > income Statement > gross Profit
7000000
Annuals > 0 > income Statement > operating Expenses
146714000
Annuals > 0 > income Statement > operating Income
-139714000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-127173000
Annuals > 0 > income Statement > net Income
-127173000
Annuals > 0 > income Statement > eps
-1.6776148117348215
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
75805840
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-137942000
Annuals > 0 > income Statement > operating Margin
-1995.9142857142858
Annuals > 0 > income Statement > total Other Income Expense Net
12541000
Annuals > 0 > balance Sheet > cash
12474000
Annuals > 0 > balance Sheet > short Term Investments
121140000
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
135895000
Annuals > 0 > balance Sheet > property Plant Equipment
35466000
Annuals > 0 > balance Sheet > total Assets
175515000
Annuals > 0 > balance Sheet > payables
7732000
Annuals > 0 > balance Sheet > short Term Debt
2700000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
44056000
Annuals > 0 > balance Sheet > equity
131459000
Annuals > 0 > cash Flow > net Income
-127173000
Annuals > 0 > cash Flow > depreciation
1772000
Annuals > 0 > cash Flow > change In Working Capital
4216000
Annuals > 0 > cash Flow > cash From Operations
-102888000
Annuals > 0 > cash Flow > capital Expenditures
764000
Annuals > 0 > cash Flow > cash From Investing
90191000
Annuals > 0 > cash Flow > cash From Financing
-120000
Annuals > 0 > cash Flow > net Change In Cash
-12817000
Annuals > 0 > ratios > PE
-1.6776148117348215
Annuals > 0 > ratios > PB
0.7755943282696506
Annuals > 0 > ratios > ROE
-96.73966788124055
Annuals > 0 > ratios > ROA
-72.45705495256816
Annuals > 0 > ratios > FCF
-103652000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-14.807428571428572
Annuals > 0 > health Score
33
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
1169000
Annuals > 1 > income Statement > gross Profit
-1169000
Annuals > 1 > income Statement > operating Expenses
132276999
Annuals > 1 > income Statement > operating Income
-132276999
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-121832000
Annuals > 1 > income Statement > net Income
-121832000
Annuals > 1 > income Statement > eps
-2.018521381726861
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
60357052
Annuals > 1 > income Statement > income Tax Expense
-1
Annuals > 1 > income Statement > EBITDA
-131108000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
10444999
Annuals > 1 > balance Sheet > cash
25291000
Annuals > 1 > balance Sheet > short Term Investments
207644000
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
235589000
Annuals > 1 > balance Sheet > property Plant Equipment
37737000
Annuals > 1 > balance Sheet > total Assets
277665000
Annuals > 1 > balance Sheet > payables
4580000
Annuals > 1 > balance Sheet > short Term Debt
1481000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
40575000
Annuals > 1 > balance Sheet > equity
237090000
Annuals > 1 > cash Flow > net Income
-121832000
Annuals > 1 > cash Flow > depreciation
1169000
Annuals > 1 > cash Flow > change In Working Capital
-10479000
Annuals > 1 > cash Flow > cash From Operations
-107063000
Annuals > 1 > cash Flow > capital Expenditures
3513000
Annuals > 1 > cash Flow > cash From Investing
-34646000
Annuals > 1 > cash Flow > cash From Financing
136395000
Annuals > 1 > cash Flow > net Change In Cash
-5314000
Annuals > 1 > ratios > PE
-2.018521381726861
Annuals > 1 > ratios > PB
0.3424026105698258
Annuals > 1 > ratios > ROE
-51.38639335273525
Annuals > 1 > ratios > ROA
-43.877334197684256
Annuals > 1 > ratios > FCF
-110576000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
33
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
3042000
Annuals > 2 > income Statement > gross Profit
-3042000
Annuals > 2 > income Statement > operating Expenses
123540000
Annuals > 2 > income Statement > operating Income
-123540000
Annuals > 2 > income Statement > interest Expense
1324000
Annuals > 2 > income Statement > pretax Income
-115438000
Annuals > 2 > income Statement > net Income
-107336000
Annuals > 2 > income Statement > eps
-2.2658306859835333
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
47371589
Annuals > 2 > income Statement > income Tax Expense
-8102000
Annuals > 2 > income Statement > EBITDA
-122216000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
8102000
Annuals > 2 > balance Sheet > cash
30605000
Annuals > 2 > balance Sheet > short Term Investments
171123000
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
204380000
Annuals > 2 > balance Sheet > property Plant Equipment
6700000
Annuals > 2 > balance Sheet > total Assets
220500000
Annuals > 2 > balance Sheet > payables
6777000
Annuals > 2 > balance Sheet > short Term Debt
1832000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
25063000
Annuals > 2 > balance Sheet > equity
195437000
Annuals > 2 > cash Flow > net Income
-115438000
Annuals > 2 > cash Flow > depreciation
1324000
Annuals > 2 > cash Flow > change In Working Capital
932000
Annuals > 2 > cash Flow > cash From Operations
-83729000
Annuals > 2 > cash Flow > capital Expenditures
3019000
Annuals > 2 > cash Flow > cash From Investing
81691000
Annuals > 2 > cash Flow > cash From Financing
815000
Annuals > 2 > cash Flow > net Change In Cash
-1223000
Annuals > 2 > ratios > PE
-2.2658306859835333
Annuals > 2 > ratios > PB
0.32601189746567943
Annuals > 2 > ratios > ROE
-54.921023143007716
Annuals > 2 > ratios > ROA
-48.67845804988662
Annuals > 2 > ratios > FCF
-86748000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
34
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
2243000
Annuals > 3 > income Statement > gross Profit
-2243000
Annuals > 3 > income Statement > operating Expenses
113735000
Annuals > 3 > income Statement > operating Income
-113735000
Annuals > 3 > income Statement > interest Expense
2041000
Annuals > 3 > income Statement > pretax Income
-111694000
Annuals > 3 > income Statement > net Income
-110779000
Annuals > 3 > income Statement > eps
-2.327175708351792
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
47602336
Annuals > 3 > income Statement > income Tax Expense
-915000
Annuals > 3 > income Statement > EBITDA
-112820000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
2041000
Annuals > 3 > balance Sheet > cash
31828000
Annuals > 3 > balance Sheet > short Term Investments
259405000
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
295115000
Annuals > 3 > balance Sheet > property Plant Equipment
5636000
Annuals > 3 > balance Sheet > total Assets
305098000
Annuals > 3 > balance Sheet > payables
7840000
Annuals > 3 > balance Sheet > short Term Debt
1740000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
19201000
Annuals > 3 > balance Sheet > equity
285897000
Annuals > 3 > cash Flow > net Income
-111694000
Annuals > 3 > cash Flow > depreciation
915000
Annuals > 3 > cash Flow > change In Working Capital
3625000
Annuals > 3 > cash Flow > cash From Operations
-83531000
Annuals > 3 > cash Flow > capital Expenditures
2323000
Annuals > 3 > cash Flow > cash From Investing
-263803000
Annuals > 3 > cash Flow > cash From Financing
164897000
Annuals > 3 > cash Flow > net Change In Cash
-182437000
Annuals > 3 > ratios > PE
-2.327175708351792
Annuals > 3 > ratios > PB
0.2239447840306124
Annuals > 3 > ratios > ROE
-38.747870736663906
Annuals > 3 > ratios > ROA
-36.30931700633895
Annuals > 3 > ratios > FCF
-85854000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
34
Valuation > metrics > PE
-0.2590883293126809
Valuation > metrics > PB
2.224114126319746
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-33.69836334438104
Profitability > metrics > ROA
-33.81621806960398
Profitability > metrics > Net Margin
-3.0346153846153845
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.6188027471213312
Risk > metrics > Interest Coverage
-48.04235294117647
Risk > final Score
-144
Risk > verdict
High
Liquidity > metrics > Current Ratio
11.0893536121673
Liquidity > metrics > Quick Ratio
11.0893536121673
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
70
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
-195
Prev Risks > 1
-6
Prev Risks > 2
31
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T01:02:39.200Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-18
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0
Earnings History > 0 > eps Estimate
-0.255
Earnings History > 0 > eps Difference
0.255
Earnings History > 0 > surprise Percent
100
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-18
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.26
Earnings History > 1 > eps Estimate
-0.3697
Earnings History > 1 > eps Difference
0.1097
Earnings History > 1 > surprise Percent
29.6727
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-14
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.41
Earnings History > 2 > eps Estimate
-0.48
Earnings History > 2 > eps Difference
0.07
Earnings History > 2 > surprise Percent
14.5833
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-05
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
-0.42
Earnings History > 3 > eps Estimate
-0.48
Earnings History > 3 > eps Difference
0.06
Earnings History > 3 > surprise Percent
12.5
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-02-13
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-0.37
Earnings History > 4 > eps Estimate
-0.4673
Earnings History > 4 > eps Difference
0.0973
Earnings History > 4 > surprise Percent
20.8217
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-10-30
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.43
Earnings History > 5 > eps Estimate
-0.47
Earnings History > 5 > eps Difference
0.04
Earnings History > 5 > surprise Percent
8.5106
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-08-12
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.46
Earnings History > 6 > eps Estimate
-0.43
Earnings History > 6 > eps Difference
-0.03
Earnings History > 6 > surprise Percent
-6.9767
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-05-07
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.42
Earnings History > 7 > eps Estimate
-0.48
Earnings History > 7 > eps Difference
0.06
Earnings History > 7 > surprise Percent
12.5
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-02-15
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-0.46
Earnings History > 8 > eps Estimate
-0.49
Earnings History > 8 > eps Difference
0.03
Earnings History > 8 > surprise Percent
6.1224
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-11-01
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-0.45
Earnings History > 9 > eps Estimate
-0.58
Earnings History > 9 > eps Difference
0.13
Earnings History > 9 > surprise Percent
22.4138
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-08-03
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
BeforeMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-0.54
Earnings History > 10 > eps Estimate
-0.63
Earnings History > 10 > eps Difference
0.09
Earnings History > 10 > surprise Percent
14.2857
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-05-08
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
BeforeMarket
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-0.58
Earnings History > 11 > eps Estimate
-0.68
Earnings History > 11 > eps Difference
0.1
Earnings History > 11 > surprise Percent
14.7059
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2023-03-15
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
BeforeMarket
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-0.6
Earnings History > 12 > eps Estimate
-0.63
Earnings History > 12 > eps Difference
0.03
Earnings History > 12 > surprise Percent
4.7619
Earnings History > 13 > period
2022-09-30
Earnings History > 13 > report Date
2022-11-14
Earnings History > 13 > date
2022-09-30
Earnings History > 13 > before After Market
BeforeMarket
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
-0.63
Earnings History > 13 > eps Estimate
-0.64
Earnings History > 13 > eps Difference
0.01
Earnings History > 13 > surprise Percent
1.5625
Earnings History > 14 > period
2022-06-30
Earnings History > 14 > report Date
2022-08-09
Earnings History > 14 > date
2022-06-30
Earnings History > 14 > before After Market
BeforeMarket
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
-0.58
Earnings History > 14 > eps Estimate
-0.61
Earnings History > 14 > eps Difference
0.03
Earnings History > 14 > surprise Percent
4.918
Earnings History > 15 > period
2022-03-31
Earnings History > 15 > report Date
2022-05-10
Earnings History > 15 > date
2022-03-31
Earnings History > 15 > before After Market
BeforeMarket
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
-0.63
Earnings History > 15 > eps Estimate
-0.65
Earnings History > 15 > eps Difference
0.02
Earnings History > 15 > surprise Percent
3.0769
Earnings History > 16 > period
2021-12-31
Earnings History > 16 > report Date
2022-03-16
Earnings History > 16 > date
2021-12-31
Earnings History > 16 > before After Market
BeforeMarket
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
-0.71
Earnings History > 16 > eps Estimate
-0.68
Earnings History > 16 > eps Difference
-0.03
Earnings History > 16 > surprise Percent
-4.4118
Earnings History > 17 > period
2021-09-30
Earnings History > 17 > report Date
2021-11-12
Earnings History > 17 > date
2021-09-30
Earnings History > 17 > before After Market
BeforeMarket
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
-0.66
Earnings History > 17 > eps Estimate
-0.62
Earnings History > 17 > eps Difference
-0.04
Earnings History > 17 > surprise Percent
-6.4516
Earnings History > 18 > period
2021-06-30
Earnings History > 18 > report Date
2021-08-12
Earnings History > 18 > date
2021-06-30
Earnings History > 18 > before After Market
BeforeMarket
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
-0.58
Earnings History > 18 > eps Estimate
-0.49
Earnings History > 18 > eps Difference
-0.09
Earnings History > 18 > surprise Percent
-18.3673
Earnings History > 19 > period
2021-03-31
Earnings History > 19 > report Date
2021-05-11
Earnings History > 19 > date
2021-03-31
Earnings History > 19 > before After Market
BeforeMarket
Earnings History > 19 > currency
USD
Earnings History > 19 > eps Actual
-0.47
Earnings History > 19 > eps Estimate
-0.42
Earnings History > 19 > eps Difference
-0.05
Earnings History > 19 > surprise Percent
-11.9048
Earnings History > 20 > period
2020-12-31
Earnings History > 20 > report Date
2021-03-16
Earnings History > 20 > date
2020-12-31
Earnings History > 20 > before After Market
BeforeMarket
Earnings History > 20 > currency
USD
Earnings History > 20 > eps Actual
-0.45
Earnings History > 20 > eps Estimate
-0.47
Earnings History > 20 > eps Difference
0.02
Earnings History > 20 > surprise Percent
4.2553
Earnings History > 21 > period
2020-09-30
Earnings History > 21 > report Date
2020-11-10
Earnings History > 21 > date
2020-09-30
Earnings History > 21 > before After Market
BeforeMarket
Earnings History > 21 > currency
USD
Earnings History > 21 > eps Actual
-5.25
Earnings History > 21 > eps Estimate
-0.43
Earnings History > 21 > eps Difference
-4.82
Earnings History > 21 > surprise Percent
-1120.9302
Earnings History > 22 > period
2020-06-30
Earnings History > 22 > report Date
2020-09-25
Earnings History > 22 > date
2020-06-30
Earnings History > 22 > before After Market
AfterMarket
Earnings History > 22 > currency
USD
Earnings History > 22 > eps Actual
-5.5
Earnings History > 22 > eps Estimate
-0.39
Earnings History > 22 > eps Difference
-5.11
Earnings History > 22 > surprise Percent
-1310.2564
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/APrelude Therapeutics stock rating reiterated at Market Outperform by Citizens Investing.com South Africa
Read more →Prelude Therapeutics Incorporated's (NASDAQ:PRLD) 66% Share Price Plunge Could Signal Some Risk simplywall.st
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$4
Analyst Picks
Strong Buy
1
Buy
2
Hold
0
Sell
1
Strong Sell
0
Sentiment:
Neutral
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Medium
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 4.40% of the total shares of Prelude Therapeutics Inc
1.
Vanguard Total Stock Mkt Idx Inv(1.2456%)
since
2025/07/31
2.
T. Rowe Price Health Sciences(1.1554%)
since
2025/07/31
3.
Biotech Growth Ord(0.6122%)
since
2025/05/31
4.
Vanguard Institutional Extnd Mkt Idx Tr(0.2519%)
since
2025/07/31
5.
Fidelity Extended Market Index(0.1837%)
since
2025/07/31
6.
Bridgeway Ultra-Small Company Market(0.1502%)
since
2025/06/30
7.
Schwab US Small-Cap ETF™(0.1428%)
since
2025/08/30
8.
TD Health Sciences - I(0.1419%)
since
2024/12/31
9.
T. Rowe Price Health Sciences Port(0.0755%)
since
2025/07/31
10.
Fidelity Total Market Index(0.0623%)
since
2025/07/31
11.
T. Rowe Price Health Sciences Equity Q(0.0583%)
since
2025/07/31
12.
Fidelity Series Total Market Index(0.0456%)
since
2025/07/31
13.
Extended Equity Market Fund K(0.0405%)
since
2025/06/30
14.
Fidelity Nasdaq Composite Index(0.0364%)
since
2025/07/31
15.
Spartan Extended Market Index Pool F(0.0361%)
since
2025/07/31
16.
Northern Trust Extended Eq Market Idx(0.0335%)
since
2025/06/30
17.
NT Ext Equity Mkt Idx Fd - L(0.0335%)
since
2025/06/30
18.
JHVIT Health Sciences I(0.0308%)
since
2025/07/31
19.
JHFunds2 Health Sciences NAV(0.0304%)
since
2025/01/31
20.
NT Ext Equity Mkt Idx Fd - NL(0.0291%)
since
2025/06/30
21.
Royal Bank of Canada(0.005%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.255
Date
2025-09-30
EPS Actual
-0.26
EPS Estimate
-0.3697
EPS Difference
0.1097
Surprise Percent
29.6727%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.